Sol-Gel Technologies Ltd. (SLGL)Healthcare | Biotechnology | Ness Ziona, Israel | NasdaqCM
73.87 USD
-1.45
(-1.925%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 73.87 Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 19, 2026, 12:43 a.m. EDT
SLGL presents a high-risk binary trade where short-term momentum is neutralized by fundamental distress (negative P/E, negative gross/operating margins) and dilution concerns; while the recent 30% price rise and oversubscribed offering signal speculative interest, the lack of profitability and lack of dividend yield make it unsuitable for long-term income or stable growth, warranting a 'Hold' or 'Avoid' stance for most investors. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.115768 |
| MSTL | 0.125508 |
| AutoETS | 0.129243 |
| AutoARIMA | 0.403255 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.30 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.453 |
| Excess Kurtosis | -0.92 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.344 |
| Revenue per Share | 6.959 |
| Market Cap | 239,728,176 |
| Forward P/E | -10.85 |
| Beta | 1.27 |
| Profit Margins | -31.60% |
| Website | https://www.sol-gel.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 11.627351 |
| Address1 | 7 Golda Meir Street |
| Address2 | Weizmann Science Park |
| All Time High | 210.0 |
| All Time Low | 3.34 |
| Ask | 74.0 |
| Ask Size | 3 |
| Average Daily Volume10 Day | 78,290 |
| Average Daily Volume3 Month | 40,914 |
| Average Volume | 40,914 |
| Average Volume10Days | 78,290 |
| Beta | 1.266 |
| Bid | 74.71 |
| Bid Size | 2 |
| Book Value | 8.187 |
| City | Ness Ziona |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 73.87 |
| Current Ratio | 4.371 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 77.22 |
| Day Low | 72.8325 |
| Debt To Equity | 4.344 |
| Display Name | Sol-Gel |
| Earnings Timestamp End | 1,777,638,600 |
| Earnings Timestamp Start | 1,777,638,600 |
| Ebitda | -7,483,000 |
| Ebitda Margins | -0.38596 |
| Enterprise To Ebitda | -24.664 |
| Enterprise To Revenue | 9.519 |
| Enterprise Value | 184,557,760 |
| Eps Current Year | -6.81 |
| Eps Forward | -6.81 |
| Eps Trailing Twelve Months | -2.19 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 78.61266 |
| Fifty Day Average Change | -4.7426605 |
| Fifty Day Average Change Percent | -0.060329475 |
| Fifty Two Week Change Percent | 1,162.7351 |
| Fifty Two Week High | 97.97 |
| Fifty Two Week High Change | -24.099998 |
| Fifty Two Week High Change Percent | -0.24599366 |
| Fifty Two Week Low | 4.11 |
| Fifty Two Week Low Change | 69.76 |
| Fifty Two Week Low Change Percent | 16.973236 |
| Fifty Two Week Range | 4.11 - 97.97 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,517,495,400,000 |
| Float Shares | 699,126 |
| Forward Eps | -6.81 |
| Forward P E | -10.847284 |
| Free Cashflow | 617,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 28 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -0.17618999 |
| Gross Profits | -3,416,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.60139 |
| Held Percent Institutions | 0.35303003 |
| Implied Shares Outstanding | 3,245,271 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,746,403,200 |
| Last Split Factor | 1:10 |
| Long Business Summary | Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. |
| Long Name | Sol-Gel Technologies Ltd. |
| Market | us_market |
| Market Cap | 239,728,176 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_621569 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -6,127,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 238,170,365 |
| Number Of Analyst Opinions | 1 |
| Open | 75.7 |
| Operating Cashflow | 322,000 |
| Operating Margins | -4.97845 |
| Payout Ratio | 0.0 |
| Phone | 972 8 931 3433 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 73.87 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 75.32 |
| Price Eps Current Year | -10.847284 |
| Price Hint | 2 |
| Price To Book | 9.022841 |
| Price To Sales Trailing12 Months | 12.364771 |
| Profit Margins | -0.31601998 |
| Quick Ratio | 4.208 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -1.45 |
| Regular Market Change Percent | -1.92512 |
| Regular Market Day High | 77.22 |
| Regular Market Day Low | 72.8325 |
| Regular Market Day Range | 72.8325 - 77.22 |
| Regular Market Open | 75.7 |
| Regular Market Previous Close | 75.32 |
| Regular Market Price | 73.87 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 40,238 |
| Return On Assets | -0.14431 |
| Return On Equity | -0.23719999 |
| Revenue Growth | 1.504 |
| Revenue Per Share | 6.959 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 3,245,270 |
| Shares Percent Shares Out | 0.0039 |
| Shares Short | 12,551 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 8,979 |
| Short Name | Sol-Gel Technologies Ltd. |
| Short Percent Of Float | 0.012200001 |
| Short Ratio | 0.33 |
| Source Interval | 15 |
| Symbol | SLGL |
| Target High Price | 110.0 |
| Target Low Price | 110.0 |
| Target Mean Price | 110.0 |
| Target Median Price | 110.0 |
| Total Cash | 23,999,000 |
| Total Cash Per Share | 8.541 |
| Total Debt | 991,000 |
| Total Revenue | 19,388,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.19 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 44.548607 |
| Two Hundred Day Average Change | 29.321396 |
| Two Hundred Day Average Change Percent | 0.6581888 |
| Type Disp | Equity |
| Volume | 40,238 |
| Website | https://www.sol-gel.com |
| Zip | 7,403,650 |